News Lilly shares disappointing A4 study results for solanezumab The drug only targets soluble amyloid beta-protein and doesn't clear amyloid plaques.
News AZ cancer drugs chalk up wins in early-stage lung cancer Tagrisso and Imfinzi show benefit as neoadjuvant and adjuvant therapy for patients with NSLC.
News Merck sets sights on Epstein-Barr virus jab with Opko deal Licensing agreement includes $50m upfront, with a total value of $922.5m, including milestones.
News Covis finally pulls preterm birth drug Makena from market Following FDA recommendation for withdrawal, Covid finally pulls premature birth drug Makena.
News Redx slumps after it abandons trial of lead cancer drug Study of porcupine inhibitor RXC004 in combination with Merck's Keytruda will continue.
News Merck makes its Foundry data tools available for free Library of tools made for Palantir's Foundry is now on the Github open-source code repository.
News Avalyn seeks $300m from its IPO Pulmonary fibrosis drug developer Avalyn prices its IPO at around $300m, as Seaport and Hemab both target $180m-plus from their listings.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
